中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Synthesis and Biological Activities of Novel GPR40 Agonists

文献类型:期刊论文

作者Huang Jing2; Guo Bin1; Zhou Xianli2
刊名Chinese Journal of Synthetic Chemistry
出版日期2016
卷号24期号:1页码:1-5
关键词2-butyne-1,4-diol GPR40 agonist benzo-dihydrofuran derivative synthesis biological activity
ISSN号1005-1511
其他题名新型GPR40激动剂的合成及其生物活性
文献子类Article
英文摘要Methyl 2-{ 6-[4-(tert-butyldimethylsilyloxy) but-2-ynyloxy]-2,3-dihydrobenzofuran-3-yl} acetate(3) was prepared by protection of 2-butyne-1,4 -diol with tert-butyldimethylsilyl chloride,then Mitsunobu reaction with methyl 2-(6-hydroxy-2,3 -dihydrobenzofuran-3-yl) acetate. Six novel benzo-dihydrofuran derivatives(7a ~ 7f) were synthesized by deprotection,Mitsunobu reaction with phenol derivatives and hydrolysis from 3. The structures were characterized by ~1H NMR,~(13)C NMR and HR-EIMS. The activities of 7a ~ 7f were tested in GPR40-transfected HEK293 cells. The results showed that 7a ~ 7f all exhibited agonistic activities on GPR40,7e and 7f were the most potent componds,with the EC_(50) of 0.593 mumol?L~(-1) and 0.596 mumol?L~(-1),respectively.
资助项目国家自然科学基金资助项目[00000000]
WOS研究方向Chemistry ; Pharmacology & Pharmacy (provided by Clarivate Analytics)
语种中文
CSCD记录号CSCD:5775406
源URL[http://119.78.100.183/handle/2S10ELR8/269242]  
专题药物化学研究室
作者单位1.Shanghai Institute of Materia Medica,Chinese Academy of Sciences, Shanghai 201203, China.
2.School of Life Science and Engineering,Southwest Jiaotong University, Chengdu, Sichuan 610031, China.;
推荐引用方式
GB/T 7714
Huang Jing,Guo Bin,Zhou Xianli. Synthesis and Biological Activities of Novel GPR40 Agonists[J]. Chinese Journal of Synthetic Chemistry,2016,24(1):1-5.
APA Huang Jing,Guo Bin,&Zhou Xianli.(2016).Synthesis and Biological Activities of Novel GPR40 Agonists.Chinese Journal of Synthetic Chemistry,24(1),1-5.
MLA Huang Jing,et al."Synthesis and Biological Activities of Novel GPR40 Agonists".Chinese Journal of Synthetic Chemistry 24.1(2016):1-5.

入库方式: OAI收割

来源:上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。